Biogen flags Q2–Q3 2026 R&D expense hit
Biogen Inc. is warning that special research and development charges will weigh on its earnings for the middle of 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Biogen Inc. is warning that special research and development charges will weigh on its earnings for the middle of 2026. For the second quarter of 2026, it expects acquired in-process research and development, upfront and milestone expense of about $164 million, which management estimates will reduce GAAP and non-GAAP net income by roughly $0.95 per diluted share.
For the third quarter of 2026, Biogen anticipates additional acquired in-process research and development, upfront and milestone expense of $290 million to $320 million, tied to potential milestones and transactions that have not yet closed. This third-quarter expense is expected to lower GAAP and non-GAAP net income by about $1.75 to $1.95 per diluted share. These costs arise from collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions.
Insights
Biogen pre-signals sizable 2026 R&D charges that will temporarily depress EPS.
Biogen outlines significant acquired in-process research and development, upfront and milestone expense in mid-2026: about $164 million in Q2 and $290–$320 million in Q3. Management quantifies the estimated impact on GAAP and non-GAAP net income per diluted share for both quarters.
These amounts stem from collaboration and license agreements, including milestones and possible asset acquisitions. Such charges are typically one-time or irregular, so they affect reported earnings but do not necessarily reflect underlying product sales or operating trends, based on the description provided.
Biogen also notes that results for the quarter ended June 30, 2026 are not yet finalized and could differ from these preliminary estimates. The company emphasizes forward-looking statement risks, highlighting that transaction timing and magnitude can change, so future filings will be key to see the final recorded expenses.
8-K Event Classification
Item 2.02 — Results of Operations and Financial Condition
1 item
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Key Figures
Q2 2026 acquired IPR&D expense: $164 million
Q2 2026 EPS impact: $0.95 per diluted share
Q3 2026 acquired IPR&D expense range: $290–$320 million
+1 more
4 metrics
Q2 2026 acquired IPR&D expense
$164 million
Estimated pre-tax acquired in-process research and development, upfront and milestone expense
Q2 2026 EPS impact
$0.95 per diluted share
Estimated reduction to GAAP and non-GAAP net income per diluted share
Q3 2026 acquired IPR&D expense range
$290–$320 million
Anticipated acquired in-process research and development, upfront and milestone expense
Q3 2026 EPS impact range
$1.75–$1.95 per diluted share
Anticipated reduction to GAAP and non-GAAP net income per diluted share
Key Terms
acquired in-process research and development, upfront and milestone expense, GAAP and non-GAAP, net income per diluted share, +2 more
6 terms
acquired in-process research and development financial
"will include acquired in-process research and development, upfront and milestone expense of approximately $164 million"
Acquired in-process research and development is the unfinished scientific work and product programs a company buys from another firm as part of a deal — think of it as buying an unfinished prototype and the team working on it. Investors care because the buyer is paying for future potential that may never materialize; that payment often shows up as a large one-time cost and signals higher risk and reward tied to future products rather than current sales.
upfront and milestone expense financial
"acquired in-process research and development, upfront and milestone expense ranging from approximately $290 million to $320 million"
GAAP and non-GAAP financial
"expects that its GAAP and non-GAAP results for the second quarter of 2026 will include"
GAAP are the standardized accounting rules companies must follow when reporting financial results, like an official recipe that ensures every baker measures ingredients the same way. Non-GAAP figures are alternative measures companies provide by removing certain items they view as one-time or unusual, similar to a baker presenting a version of a recipe with optional tweaks. Investors care because GAAP lets you compare companies consistently, while non-GAAP can highlight management’s view of core performance but may make results look better than the standard numbers.
forward-looking statements regulatory
"Note Regarding Forward-Looking Statements This on contains forward-looking statements relating to our financial and operating results"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What drives Biogen’s acquired in-process research and development expense?
Biogen’s acquired in-process research and development, upfront and milestone expense comes from collaboration and license agreements. It includes upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions related to in-process research and development.
Does Biogen regularly forecast acquired in-process R&D and milestone expenses?
Biogen states that it does not forecast acquired in-process research and development, upfront and milestone expense. The company cites uncertainty in the future occurrence, magnitude and timing of these transactions in any given period as the reason.
Are Biogen’s Q2 2026 financial results finalized yet?
No. Biogen notes that results for the quarter ended June 30, 2026 have not been finalized. They remain subject to the company’s financial statement closing procedures, and final results may differ from the preliminary unaudited estimates discussed.
What caution does Biogen give about its forward-looking expense estimates?
Biogen explains that its estimates are forward-looking statements based on current beliefs and available information. It cautions that risks, uncertainties or inaccurate assumptions could cause actual results to differ materially from the expense and earnings impacts described.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices; Zip Code)
Registrant’s telephone number, including area code: (617 ) 679-2000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the second quarter of 2026 by approximately $0.95 per share.
Additionally, Biogen anticipates its GAAP and non-GAAP results for the third quarter of 2026 to include acquired in-process research and development, upfront and milestone expense ranging from approximately $290 million to $320 million relating to potential milestones and transactions that have not yet closed. The estimated charge is anticipated to impact GAAP and non-GAAP net income per diluted share for the third quarter of 2026 ranging from approximately $1.75 to $1.95 per share.
Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development. Biogen does not forecast such acquired in-process research and development, upfront and milestone expense due to the uncertainty of the future occurrence, magnitude and timing of these transactions in any given period.
Results for the quarter ended June 30, 2026, have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from the preliminary unaudited estimates described herein.
Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements relating to our financial and operating results and financial guidance, that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the “Safe Harbor” provisions of the PSLRA. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” "assume," “believe,” “contemplate,” “continue," "could," “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” "outlook," “plan,” “possible,” "potential," “predict,” “project,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning.
Given their forward-looking nature, these statements involve substantial risks and uncertainties and may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. The information above includes, among others, forward-looking statements reflecting management’s current intentions and expectations for the future with respect to Biogen’s estimated acquired in-process research and development, upfront and milestone expense for the quarter ended June 30, 2026, and the related impact to Biogen’s GAAP and non-GAAP earnings per share for such period. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part.
These statements speak only as of the date of this Current Report on Form 8-K and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biogen Inc.
By: /s/ Wendell Taylor
Wendell Taylor
Secretary
Date: July 1, 2026